Active, Not Recruiting
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395
- Conditions
- Bites and Stings, Chemically-Induced Disorders, Extensive Stage Small Cell Lung Cancer, +9 more
- Locations
-
- University of Southern California, Norris Comprehensive Cancer Center Los Angeles, California, United States
- Christiana Care Health Services Newark, Delaware, United States
- Henry Ford Health System Detroit, Michigan, United States
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States